394 studies found for:    biogen | biogen
Show Display Options
Rank Status Study
21 Completed Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient
Condition: Healthy
Intervention: Drug: BG00012
22 Available Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
Condition: Infantile-onset Spinal Muscular Atrophy (SMA)
Intervention: Drug: nusinersen
23 Completed Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Interferon-beta-1a;   Drug: methylprednisolone
24 Completed A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Procedure: Plasma exchange;   Drug: natalizumab treatment
25 Completed A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis
Condition: Exercise
Intervention:
26 Completed Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers
Condition: Healthy
Interventions: Drug: BIIB014;   Other: [11C]SCH442416
27 Completed Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: BIIB014;   Drug: Placebo
28 Recruiting A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Intervention: Drug: Nusinersen
29 Not yet recruiting MS PATHS Normative Sub-Study
Condition: Multiple Sclerosis (MS)
Intervention:
30 Recruiting New Formulation and Food Effect Study of BIIB074
Conditions: Trigeminal Neuralgia (TN);   Other Neuropathic Pain
Interventions: Drug: BIIB074 Treatment A;   Drug: BIIB074 Treatment B;   Drug: BIIB074 Treatment C;   Drug: BIIB074 Treatment D
31 Not yet recruiting Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: Daclizumab
32 Recruiting Study to Evaluate BIIB059 in CLE With or Without SLE
Conditions: Systemic Lupus Erythematosus (SLE);   Active Cutaneous Lupus Erythematosus (CLE)
Interventions: Drug: BIIB059;   Drug: Placebo
33 Recruiting PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants
Condition: Trigeminal Neuralgia
Interventions: Drug: BIIB074;   Drug: Placebo
34 Recruiting A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants
Condition: Systemic Lupos Erythematosus, SLE
Interventions: Drug: BIIB068;   Drug: Placebo
35 Recruiting Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Condition: Acute Ischemic Stroke
Interventions: Drug: natalizumab;   Drug: Placebo
36 Recruiting Single and Multiple Dose Study of BIIB067 (Isis-SOD1Rx) in Adults With Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: BIIB067 (Isis-SOD1Rx);   Other: Placebo
37 Recruiting Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Condition: Amyotrophic Lateral Sclerosis (ALS)
Intervention:
38 Recruiting Plegridy Satisfaction Study in Participants
Condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: peginterferon beta-1a
39 Recruiting Tecfidera and the Gut Microbiota
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: dimethyl fumarate;   Drug: injectable MS DMT
40 Recruiting Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: BIIB054;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.